Christophe Corpechot

16.0k total citations · 3 hit papers
115 papers, 7.9k citations indexed

About

Christophe Corpechot is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Christophe Corpechot has authored 115 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Hepatology, 78 papers in Epidemiology and 52 papers in Surgery. Recurrent topics in Christophe Corpechot's work include Liver Diseases and Immunity (89 papers), Liver Disease Diagnosis and Treatment (75 papers) and Pediatric Hepatobiliary Diseases and Treatments (37 papers). Christophe Corpechot is often cited by papers focused on Liver Diseases and Immunity (89 papers), Liver Disease Diagnosis and Treatment (75 papers) and Pediatric Hepatobiliary Diseases and Treatments (37 papers). Christophe Corpechot collaborates with scholars based in France, Italy and United Kingdom. Christophe Corpechot's co-authors include Olivier Chazouillères, Raoul Poupon, Raoul Poupon, Yves Chrétien, Dominique Wendum, Fabrice Carrat, Gideon M. Hirschfield, Pietro Invernizzi, Christoph Schramm and Chantal Housset and has published in prestigious journals such as Nature, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Christophe Corpechot

103 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia

1996 1.5k citations Christophe Corpechot et al. profile →
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

2017 886 citations Christophe Corpechot et al. Journal of Hepatology profile →
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients

1997 500 citations Christophe Corpechot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christophe Corpechot France	37	4.8k	4.1k	2.8k	1.5k	1.0k	115	7.9k
Helen Remotti United States	35	433 0.1×	1.5k 0.4×	4.2k 1.5×	795 0.5×	1.9k 1.9×	118	9.6k
Béatrice Parfait France	30	246 0.1×	717 0.2×	616 0.2×	833 0.6×	1.5k 1.5×	83	3.3k
Kathleen M. Loomes United States	36	487 0.1×	423 0.1×	1.6k 0.6×	126 0.1×	1.2k 1.2×	103	3.1k
Luca Fabris Italy	42	1.7k 0.3×	885 0.2×	2.7k 1.0×	56 0.0×	950 0.9×	129	4.5k
Reza Zarnegar United States	41	4.4k 0.9×	1.2k 0.3×	2.7k 1.0×	92 0.1×	2.8k 2.7×	77	6.7k
Kunihito Gotoh Japan	36	844 0.2×	1.2k 0.3×	1.5k 0.5×	101 0.1×	1.1k 1.1×	178	4.2k
Carl Atkinson United States	38	306 0.1×	419 0.1×	1.1k 0.4×	140 0.1×	1.1k 1.1×	141	4.9k
Kazuyuki Ishida Japan	33	294 0.1×	661 0.2×	1.1k 0.4×	403 0.3×	799 0.8×	190	3.4k
Nam Keun Kim South Korea	36	142 0.0×	480 0.1×	435 0.2×	360 0.2×	2.6k 2.5×	305	5.6k
Richard K. Burt United States	42	164 0.0×	735 0.2×	973 0.4×	481 0.3×	1.0k 1.0×	167	6.9k

Countries citing papers authored by Christophe Corpechot

Since Specialization

Citations

This map shows the geographic impact of Christophe Corpechot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Corpechot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Corpechot more than expected).

Fields of papers citing papers by Christophe Corpechot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Corpechot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Corpechot. The network helps show where Christophe Corpechot may publish in the future.

Co-authorship network of co-authors of Christophe Corpechot

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Corpechot. A scholar is included among the top collaborators of Christophe Corpechot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Corpechot. Christophe Corpechot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Untas, Aurélie, Cécile Flahault, Christel Vioulac, et al.. (2025). PBC-HOPE: A Randomized Controlled Trial of Hypnosis and Psychoeducation in Women With Primary Biliary Cholangitis and Fatigue. The American Journal of Gastroenterology.

Corpechot, Christophe, Karima Ben Belkacem, Farid Gaouar, et al.. (2025). Epidemiology, comorbidities, treatments and outcomes of autoimmune liver diseases: A French nationwide study. JHEP Reports. 7(11). 101546–101546.

Yimam, Kidist, Alan Bonder, Kessendri Reddy, et al.. (2025). Alkaline Phosphatase Changes With Seladelpar Across Subgroups Of Primary Biliary Cholangitis Patients In The Response Trial. Digestive and Liver Disease. 57. S88–S88.

Khakoo, Nidah S., John Reynolds, Christophe Corpechot, et al.. (2025). Comparative effectiveness of peroxisome proliferator–activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis. Hepatology. 83(4). 721–734. 2 indexed citations

Montaño‐Loza, Aldo J., Christophe Corpechot, Patrizia Burra, et al.. (2024). Recurrence of autoimmune liver diseases after liver transplantation: Review and expert opinion statement. Liver Transplantation. 31(3). 369–383. 4 indexed citations

Cazzagon, Nora, S. El Mouhadi, Carlos Ferreira, et al.. (2022). Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis. JHEP Reports. 4(11). 100577–100577. 15 indexed citations

Corpechot, Christophe, Alexandra Heurgué, Pascal Potier, et al.. (2021). Non-invasive diagnosis and follow-up of primary biliary cholangitis. Clinics and Research in Hepatology and Gastroenterology. 46(1). 101770–101770. 5 indexed citations

Tanaka, Atsushi, Junko Hirohara, Toshiaki Nakano, et al.. (2021). Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology. 75(3). 565–571. 71 indexed citations

Cazzagon, Nora, Olivier Chazouillères, Christophe Corpechot, et al.. (2019). Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology. 43(4). 387–394. 7 indexed citations

10.

Lemoinne, Sara, Astrid Kemgang, Karima Ben Belkacem, et al.. (2019). Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 69(1). 92–102. 146 indexed citations

11.

Dahlqvist, Géraldine, Farid Gaouar, Fabrice Carrat, et al.. (2016). Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 65(1). 152–163. 77 indexed citations

12.

Sasso, M., Astrid Kemgang, Farid Gaouar, et al.. (2015). Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. Ultrasound in Medicine & Biology. 42(1). 92–103. 108 indexed citations

13.

Corpechot, Christophe. (2015). Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases. Clinics in Liver Disease. 20(1). 143–158. 13 indexed citations

14.

Corpechot, Christophe, Farid Gaouar, Ahmed El Naggar, et al.. (2014). Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis. Gastroenterology. 146(4). 970–979.e6. 196 indexed citations

15.

Corpechot, Christophe, Olivier Chazouillères, & Raoul Poupon. (2011). Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology. 55(6). 1361–1367. 276 indexed citations

16.

Corpechot, Christophe & Olivier Chazouillères. (2010). Hépatites auto-immunes : actualités diagnostiques et thérapeutiques. La Revue de Médecine Interne. 31(9). 606–614. 8 indexed citations

17.

Corpechot, Christophe, Fabrice Carrat, Abbas Bahr, et al.. (2005). The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 128(2). 297–303. 261 indexed citations

18.

Corpechot, Christophe, Armelle Poujol‐Robert, Dominique Wendum, et al.. (2004). Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA‐treated patients with primary biliary cirrhosis. Liver International. 24(3). 187–193. 33 indexed citations

19.

Corpechot, Christophe, Véronique Barbu, Dominique Wendum, et al.. (2002). Hepatocyte Growth Factor and c-Met Inhibition by Hepatic Cell Hypoxia. American Journal Of Pathology. 160(2). 613–620. 65 indexed citations

20.

Corpechot, Christophe, et al.. (2000). The Effect of Ursodeoxycholic Acid Therapy on Liver Fibrosis Progression in Primary Biliary Cirrhosis. Hepatology. 32(6). 1196–1199. 222 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact